Compare NOM & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NOM | NEUP |
|---|---|---|
| Founded | 1993 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.7M | 21.7M |
| IPO Year | N/A | N/A |
| Metric | NOM | NEUP |
|---|---|---|
| Price | $11.42 | $3.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 6.9K | ★ 45.4K |
| Earning Date | 01-01-0001 | 02-13-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,649,448.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.52 | $3.65 |
| 52 Week High | $10.48 | $21.40 |
| Indicator | NOM | NEUP |
|---|---|---|
| Relative Strength Index (RSI) | 48.03 | 44.45 |
| Support Level | $10.99 | $3.98 |
| Resistance Level | $11.85 | $4.18 |
| Average True Range (ATR) | 0.31 | 0.14 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 43.00 | 13.79 |
Nuveen Missouri Quality Municipal Income Fund is a diversified, closed-end management investment company operating in the United States. The Fund's investment objective is current income exempt from both regular federal income taxes and Missouri personal income taxes, and to enhance portfolio value relative to the Missouri municipal bond market by investing in tax-exempt Missouri municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued. The fund invests in municipal securities as well as floating rate securities, and derivatives such as futures, options, and swap contracts to the necessary extent.
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.